Arcellx (ACLX) Other financing activities (2021 - 2025)
Arcellx's quarterly Other financing activities came in at $38.4 million in Q3 2025, up 192010.0% quarter-over-quarter from $20000.0 in Q4 2021.
Arcellx has reported Other financing activities for 2 years, with the latest figure at $38.4 million in Q3 2025.
- For the quarter ending Q3 2025, Other financing activities changed N/A year-over-year to $38.4 million; the trailing twelve-month figure through Sep 2025 stood at $39.1 million (changed N/A YoY), and the FY2025 full-year result was $38.4 million, changed N/A from the prior year.
- Other financing activities for Q3 2025 stood at $38.4 million, up from $20000.0 in the prior quarter.
- The five-year high for Other financing activities was $38.4 million in Q3 2025, with the low at $14000.0 in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 38.42 Mn |
| Sep 30, 2025 | 38.42 Mn |
| Dec 31, 2021 | 20,000.00 |
| Dec 31, 2021 | 20,000.00 |
| Sep 30, 2021 | 625,000.00 |
| Sep 30, 2021 | 625,000.00 |
| Jun 30, 2021 | 29,000.00 |
| Jun 30, 2021 | 29,000.00 |
| Mar 31, 2021 | 14,000.00 |
| Mar 31, 2021 | 14,000.00 |